Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Clyde Jones

Hematology & Oncology Memphis, TN Medical Doctor

NPI 1477557064 CMS profile 339376

80 Humphreys Center Dr Ste 330, Memphis, TN 38120

Open in the dashboard

General payments

$54,112

461 records reported · program years 2019–2024

Research payments

$2,457

Paid to them · 9 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$49,796 paid to institutions, not to them · program years 2019–2023

Through program year 2024, Clyde Jones of Memphis, TN is reported in the CMS Open Payments database as having received $54,112 across 461 general payments and $2,457 in research payments paid to them. Separately, studies naming them as principal investigator received $49,796 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $19 1
2023 General $503 22
2022 General $17,299 151
2022 Research $2,457 9
2021 General $3,947 70
2020 General $2,964 68
2019 General $29,380 149

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clyde Jones
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Clyde Jones were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Clyde Jones Hematology & Oncology median Middle half National median
2019 $29,380 $529 $121–$2,516 $163
2020 $2,964 $339 $82–$2,213 $114
2021 $3,947 $263 $49–$1,965 $132
2022 $17,299 $416 $103–$2,395 $149
2023 $503 $542 $125–$2,646 $160
2024 $19 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. E.R. Squibb & Sons, L.L.C. $46,504 96 payments
  2. Celgene Corporation $1,177 20 payments
  3. AstraZeneca Pharmaceuticals LP $627 18 payments
  4. GlaxoSmithKline, LLC. $616 11 payments
  5. Novartis Pharmaceuticals Corporation $402 28 payments
  6. Merck Sharp & Dohme Corporation $372 23 payments
  7. Janssen Biotech, Inc. $340 27 payments
  8. Amgen Inc. $314 18 payments
  9. Eisai Inc. $278 15 payments
  10. Lilly USA, LLC $265 15 payments
  11. Other $3,216 190 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $36,600 7 payments
  2. Food and Beverage $7,433 424 payments
  3. Consulting Fee $7,250 17 payments
  4. Travel and Lodging $2,669 6 payments
  5. Education $160 7 payments
Products named General payments · program years 2019–2024
  1. OPDIVO $35,250 63 payments
  2. EMPLICITI $5,955 8 payments
  3. BLENREP $463 2 payments
  4. CALQUENCE $326 6 payments
  5. KEYTRUDA $279 17 payments
  6. Lenvima $278 15 payments
  7. VERZENIO $230 13 payments
  8. TASIGNA $173 13 payments
  9. Pomalyst $170 12 payments
  10. IMBRUVICA $161 13 payments
  11. Other $6,045 370 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Aveo Pharmaceuticals, Inc. $2,457 9 payments

Records

470 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record